Literature DB >> 24681289

Case-control analysis of maternal prenatal analgesic use and cardiovascular malformations: Baltimore-Washington Infant Study.

Courtney A Marsh1, Janet D Cragan2, C J Alverson2, Adolfo Correa3.   

Abstract

OBJECTIVE: We sought to assess maternal prenatal use of analgesics and risk of cardiovascular malformations (CVM) in the offspring. STUDY
DESIGN: Data from the Baltimore-Washington Infant Study, a population-based case-control investigation of CVM, were used to examine selected isolated CVM diagnoses and maternal analgesic use during the periconceptional period (3 months before and after conception). We compared case and control infants on frequency of maternal use of analgesics and estimated adjusted odds ratios (adjORs) and 95% confidence intervals (CI) with logistic regression models for specific CVM phenotypes.
RESULTS: Frequency of periconceptional use of any analgesic was 52% among control mothers and 53% among case mothers. Analyses by CVM diagnoses identified an association of tetralogy of Fallot with maternal acetaminophen use (adjOR, 1.6; 95% CI, 1.1-2.3) and dextrotransposition of the great arteries with intact ventricular septum with maternal nonsteroidal antiinflammatory drug use (adjOR, 3.2; 95% CI, 1.2-8.7).
CONCLUSION: Analgesic use during the periconceptional period was not associated with CVM in the aggregate or with most phenotypes of CVM examined. Associations with 2 phenotypes of CVM may have occurred by chance. These findings warrant corroboration and further study, including further evaluation of the observed associations, the dose of analgesic taken, more specific timing of analgesic use, and indications for use.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  analgesics; birth defects; cardiovascular malformations; congenital heart defects; pregnancy

Mesh:

Substances:

Year:  2014        PMID: 24681289      PMCID: PMC4406339          DOI: 10.1016/j.ajog.2014.03.054

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  26 in total

Review 1.  NSAIDs and developmental toxicity.

Authors:  Melissa S Tassinari; Jon C Cook; Mark E Hurtt
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2003-02

2.  Interrupted aortic arch: an epidemiologic study.

Authors:  C A Loffredo; C Ferencz; P D Wilson; I W Lurie
Journal:  Teratology       Date:  2000-05

3.  Nonsteroidal antiinflammatory drug use among women and the risk of birth defects.

Authors:  Rohini K Hernandez; Martha M Werler; Paul Romitti; Lixian Sun; Marlene Anderka
Journal:  Am J Obstet Gynecol       Date:  2011-12-01       Impact factor: 8.661

4.  Nonsteroidal anti-inflammatory drugs in early pregnancy.

Authors:  A Ericson; B A Källén
Journal:  Reprod Toxicol       Date:  2001 Jul-Aug       Impact factor: 3.143

5.  Prescription, over-the-counter, and herbal medicine use in a rural, obstetric population.

Authors:  Douglas D Glover; Mayur Amonkar; Blanche F Rybeck; Timothy S Tracy
Journal:  Am J Obstet Gynecol       Date:  2003-04       Impact factor: 8.661

6.  Aspirin and congenital malformations.

Authors:  D Slone; V Siskind; O P Heinonen; R R Monson; D W Kaufman; S Shapiro
Journal:  Lancet       Date:  1976-06-26       Impact factor: 79.321

Review 7.  Analysis of the nonsteroidal anti-inflammatory drug literature for potential developmental toxicity in rats and rabbits.

Authors:  Jon C Cook; Catherine F Jacobson; Feng Gao; Melissa S Tassinari; Mark E Hurtt; John M DeSesso
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2003-02

8.  Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure.

Authors:  G D Cappon; J C Cook; M E Hurtt
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2003-02

9.  Comparison of developmental toxicology of aspirin (acetylsalicylic acid) in rats using selected dosing paradigms.

Authors:  Utpal Gupta; Jon C Cook; Melissa S Tassinari; Mark E Hurtt
Journal:  Birth Defects Res B Dev Reprod Toxicol       Date:  2003-02

10.  Maternal use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), and muscular ventricular septal defects.

Authors:  Mario A Cleves; Van H Savell; Sarika Raj; Weizhi Zhao; Adolfo Correa; Martha M Werler; Charlotte A Hobbs
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2004-03
View more
  5 in total

1.  Risk comparison for prenatal use of analgesics and selected birth defects, National Birth Defects Prevention Study 1997-2011.

Authors:  Julia D Interrante; Elizabeth C Ailes; Jennifer N Lind; Marlene Anderka; Marcia L Feldkamp; Martha M Werler; Lockwood G Taylor; James Trinidad; Suzanne M Gilboa; Cheryl S Broussard
Journal:  Ann Epidemiol       Date:  2017-09-20       Impact factor: 3.797

2.  Prescribed opioid analgesics in early pregnancy and the risk of congenital anomalies: a population-based cohort study.

Authors:  Alexa C Bowie; Martha M Werler; Maria P Velez; Wenbin Li; Andi Camden; Astrid Guttmann; Susan B Brogly
Journal:  CMAJ       Date:  2022-02-07       Impact factor: 8.262

Review 3.  Maternal Paracetamol Intake During Pregnancy-Impacts on Offspring Reproductive Development.

Authors:  Rieko Tadokoro-Cuccaro; Benjamin G Fisher; Ajay Thankamony; Ken K Ong; Ieuan A Hughes
Journal:  Front Toxicol       Date:  2022-04-14

4.  Ibuprofen results in alterations of human fetal testis development.

Authors:  Millissia Ben Maamar; Laurianne Lesné; Kristin Hennig; Christèle Desdoits-Lethimonier; Karen R Kilcoyne; Isabelle Coiffec; Antoine D Rolland; Cécile Chevrier; David M Kristensen; Vincent Lavoué; Jean-Philippe Antignac; Bruno Le Bizec; Nathalie Dejucq-Rainsford; Rod T Mitchell; Séverine Mazaud-Guittot; Bernard Jégou
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

5.  Prenatal Opioid Analgesics and the Risk of Adverse Birth Outcomes.

Authors:  Susan B Brogly; Maria P Velez; Martha M Werler; Wenbin Li; Andi Camden; Astrid Guttmann
Journal:  Epidemiology       Date:  2021-05-01       Impact factor: 4.860

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.